shutterstock_1463056853_poptika

Poptika / Shutterstock.com

28 September 2021BiotechnologyMuireann Bolger

LSPN LIVE 2021: an ‘unmissable opportunity’

Over the past year, the life sciences sector has proved to be of vital importance in the fight against COVID-19. Now more than ever, it is imperative that IP professionals are best positioned to protect and leverage innovation in this fast-paced industry.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

article

LSPN Connect: how COVID crystallised Oxford Uni’s licensing mission

1 February 2021 The COVID-19 pandemic has brought into sharp relief the crucial role that universities play in cutting-edge innovation. One story of the past year is the collaboration between research institutions such as Oxford University, and commercial entities like AstraZeneca, to rapidly bring a life-saving product to market.

LSPN Connect: Monetising your IP portfolio

15 February 2021 Chances are, if you manage a life sciences portfolio, you had to rethink your monetization strategy last year.

More on this story

article

LSPN Connect: how COVID crystallised Oxford Uni’s licensing mission

1 February 2021 The COVID-19 pandemic has brought into sharp relief the crucial role that universities play in cutting-edge innovation. One story of the past year is the collaboration between research institutions such as Oxford University, and commercial entities like AstraZeneca, to rapidly bring a life-saving product to market.

LSPN Connect: Monetising your IP portfolio

15 February 2021 Chances are, if you manage a life sciences portfolio, you had to rethink your monetization strategy last year.

More on this story

article

LSPN Connect: how COVID crystallised Oxford Uni’s licensing mission

1 February 2021 The COVID-19 pandemic has brought into sharp relief the crucial role that universities play in cutting-edge innovation. One story of the past year is the collaboration between research institutions such as Oxford University, and commercial entities like AstraZeneca, to rapidly bring a life-saving product to market.

LSPN Connect: Monetising your IP portfolio

15 February 2021 Chances are, if you manage a life sciences portfolio, you had to rethink your monetization strategy last year.

More features

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent